Mayzent approval boosts Novartis' big blockbuster plan

27 March 2019

Leaders at Swiss pharma giant Novartis (NOVN: VX) hope that 2019 could see the launch of up to four new drugs that go on to become blockbusters, and the first of these won an approval in the USA on Tuesday.

Mayzent (siponimod) is the only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS), and is expected to be available in the USA within a week.

Up to 80% of patients with relapsing remitting MS (RRMS) will develop SPMS, a debilitating form of the disease characterized by progressive and irreversible neurological disability.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK